additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Search
Boehringer Ingelheim announces appointments
Boehringer Ingelheim announces appointments
Facts About Asthma
Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
FRONTLINE
indicated for the treatment and prevention of fleas, ticks and chewing lice in dogs and cats, and aids in the control of sarcoptic mange in dogs.
Why is Diversity, Equity and Inclusion important to us?
Why is Diversity, Equity and Inclusion important to us?
Something learnt
We know that to really thrive as a company, we have to help our teams to continue to grow in their careers. Here are some of things they have learnt at work.
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
On two wheels for more animal health
Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
Human-dog relationship – a historical perspective
The human-dog relationship – a historical perspective
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Iclepertin: GlyT1 inhibitor
Iclepertin: GlyT1 inhibitor
Early Access Treatments & Compassionate Use Programs
Explore how we facilitate patient access to investigational and/or unlicensed medicines through our individual requests and Compassionate Use programs
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Fencovis®
Indicated for infectious diseases in cattle
Social innovation: catalyst for sustainable health solutions
Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
Ezabenlimab, PD-1 antibody
Ezabenlimab, PD-1 antibody
BULTAVO 3
Indicated for bluetongue disease serotype 3 in sheep and cattle
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
Investment of 65 million euro in avian vaccines in France
Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
The Core of our Leitbild
Who we are and what we strive for
Global language learning platform for our people
One global learning platform for languages, countless opportunities to grow your career
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.